These incongruous results could be explained by the different cell types used in the two studies (MEF and human breast cancer cell, respectively) or by the different methods used for manipulating phosphorylation, which might result in differences in site-specific phosphorylation of RB1 [88]. The gene discussed is RB1; the disease is breast carcinoma.